

Medical Device Alert

Ref: MDA/2013/006 Issued: 21 February 2013 at 10:00

Device

Infusion pumps.

Plum A+ and A+3 family of infusers.

Manufactured by Hospira.

All models and list numbers.



Problem	Action
<p>Risk of interruption to treatment.</p> <p>If the pump is running on mains power and the software detects that the battery cannot be fully recharged, an alarm will sound and the infusion will stop.</p> <p>If this occurs the “E321” error message will be displayed.</p> <p>The MHRA continues to investigate this and other recent field safety corrective actions.</p>	<ul style="list-style-type: none"> • Identify affected pumps. • Consider using an alternative device, particularly if an interruption to an infusion could compromise patient safety. • If an alternative is not available, follow the advice in the manufacturer’s Field Safety Notice (dated 19 February 2013) • Ensure staff also follow the advice in other Field Safety Notices issued by the manufacturer for the following problems: <ul style="list-style-type: none"> > volume control knob > door roller assembly > distal pressure sensor calibration > fluid ingress > fluid shield diaphragm > distal pressure sensor pin fracture > recycling/rebooting.
Action by	
<p>All medical, nursing and technical staff involved in the use of these devices.</p>	
CAS deadlines	Contact
<p>Action underway: 07 March 2013</p> <p>Action complete: 21 March 2013</p> <p>Note: These deadlines are for systems to be in place to identify pumps and ensure users are aware of the problems.</p>	<p>Manufacturer John McIlvaney Hospira UK Limited Tel: 0800 028 7304 Email: custserv@hospira.com</p>

Distribution

This MDA has been sent to:

- NHS trusts in England (Chief Executives)
- Care Quality Commission (CQC) (Headquarters) for information
- HSC trusts in Northern Ireland (Chief Executives)
- NHS boards in Scotland (Equipment Co-ordinators)
- Local authorities in Scotland (Equipment Co-ordinators)
- NHS boards and trusts in Wales (Chief Executives)
- Primary care trusts in England (Chief Executives)

Onward distribution

Please bring this notice to the attention of relevant employees in your establishment. Below is a suggested list of recipients.

Trusts

CAS and SABS (NI) liaison officers for onward distribution to all relevant staff including:

- A&E departments
- Adult intensive care units
- All wards
- Biomedical engineering staff
- Biomedical science departments
- Clinical governance leads
- Day surgery units
- EBME departments
- Equipment stores
- In-house maintenance staff
- IV nurse specialists
- Maintenance staff
- Medical directors
- Nursing executive directors
- Oncology units
- Paediatric intensive care units
- Risk managers
- Supplies managers
- Theatres

Primary care trusts

CAS liaison officers for onward distribution to all relevant staff including:

- Community hospitals
- Equipment libraries and stores
- Health visitors
- Hospital at home
- Palliative care teams

Independent distribution

Establishments registered with the Care Quality Commission (CQC) (England only)

This alert should be read by:

- Care homes providing nursing care (adults)
- Clinics
- Hospices
- Hospitals in the independent sector
- Independent treatment centres

Please note: CQC and OFSTED do not distribute these alerts. Independent healthcare providers and social care providers can sign up to receive MDAs directly from the Department of Health's Central Alerting System (CAS) by sending an email to: safetyalerts@dh.gsi.gov.uk and requesting this facility.

Contacts

Manufacturer

John McIlvaney
Customer Services Manager
Hospira UK
Queensway
Royal Leamington Spa
Tel: 0800 028 7304
Fax: 0800 028 7305
Email: custserv@hospira.com

England

If you are in England, please send enquiries about this notice to the MHRA, quoting reference number **MDA/2013/006** or **2013/002/004/291/031**

Technical aspects

Sharon Knight or Roopa Prabhakar
Medicines & Healthcare products Regulatory Agency
Floor 4
151 Buckingham Palace Road
London SW1W 9SZ
Tel: 020 3080 7202/7293
Fax: 020 8754 3965
Email: sharon.knight@mhra.gsi.gov.uk
roopa.prabhakar@mhra.gsi.gov.uk

Clinical aspects

Mark Grumbridge
Medicines & Healthcare products Regulatory Agency
Floor 4
151 Buckingham Palace Road
London SW1W 9SZ
Tel: 020 3080 7128
Fax: 020 8754 3965
Email: mark.grumbridge@mhra.gsi.gov.uk

How to report adverse incidents

Please report via our website <http://www.mhra.gov.uk>
Further information about **CAS** can be found at <https://www.cas.dh.gov.uk/Home.aspx>

Northern Ireland

Alerts in Northern Ireland will continue to be distributed via the NI SABS system.

Enquiries and adverse incident reports in Northern Ireland should be addressed to:

Northern Ireland Adverse Incident Centre

Health Estates Investment Group

Room 17

Annex 6

Castle Buildings

Stormont Estate

Dundonald BT4 3SQ

Tel: 02890 523 704

Fax: 02890 523 900

Email: NIAIC@dhsspsni.gov.uk

<http://www.dhsspsni.gov.uk/index/hea/niaic.htm>

How to report adverse incidents in Northern Ireland

Please report directly to NIAIC, further information can be found on our website <http://www.dhsspsni.gov.uk/niaic>

Further information about **SABS** can be found at <http://sabs.dhsspsni.gov.uk/>

Scotland

Enquiries and adverse incident reports in Scotland should be addressed to:

Incident Reporting and Investigation Centre

Health Facilities Scotland

NHS National Services Scotland

Gyle Square

1 South Gyle Crescent

Edinburgh EH12 9EB

Tel: 0131 275 7575

Fax: 0131 314 0722

Email: nss.irc@nhs.net

<http://www.hfs.scot.nhs.uk/online-services/incident-reporting-and-investigation-centre-irc/>

Wales

Enquiries in Wales should be addressed to:

Improving Patient Safety Team

Medical Directorate

Welsh Government

Cathays Park

Cardiff CF10 3NQ

Tel: 029 2082 3922

Email: Haz-Aic@wales.gsi.gov.uk

MHRA is an executive agency of the Department of Health

© Crown Copyright 2013

Addressees may take copies for distribution within their own organisations